The 1518.HK stock slid 18.46% intraday on 06 Mar 2026, closing at HK$0.53 on the HKSE in Hong Kong. Volume surged to 46,500 shares versus an average of 12,412, raising intraday volatility. The drop followed a weak open at HK$0.60 and left price testing the day low of HK$0.52. This piece examines catalysts, valuation, technical risk, and a short-term forecast for New Century Healthcare Holding Co. Limited, with data-driven analysis for traders watching top losers today.

1518.HK stock intraday price action and drivers

New Century Healthcare (1518.HK) fell from a previous close of HK$0.65 to HK$0.53 today on the HKSE. The move represents a -18.46% one-day change and a relative volume spike of 15.11x. Traders pointed to thin liquidity and negative sentiment in small-cap healthcare names. The stock is trading well below its 50-day average of HK$0.65 and 200-day average of HK$0.79, signalling short-term selling pressure.

Valuation and financial snapshot for 1518.HK stock

On fundamentals, New Century reports EPS -0.10 and a negative PE of -6.20, reflecting recent losses. Key ratios show cheap multiples: P/S 0.31 and P/B 0.47. Cash per share is HK$0.69, and book value per share is HK$0.91. Market cap stands at HK$302,529,930 with 487,951,500 shares outstanding. The company yields roughly 4.17% on trailing dividend metrics, but payout is constrained by negative earnings.

Technicals and support levels for 1518.HK stock

Technicals show oversold momentum: RSI 19.63 and CCI -313.24. Short-term bands sit at BB lower HK$0.58 and BB upper HK$0.68. Immediate support is the day low HK$0.52 and the year low HK$0.42. ADX at 31.40 indicates a strong trend. Traders should watch 50-day MA HK$0.65 and 200-day MA HK$0.79 as resistance. Low liquidity increases execution risk for larger orders.

Meyka AI rates 1518.HK with a score out of 100 and forecast

Meyka AI rates 1518.HK with a score of 71.66 out of 100 and assigns a B+ (BUY) suggestion. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Meyka AI’s forecast model projects monthly HK$0.68, quarterly HK$0.79, and yearly HK$0.62 versus the current HK$0.53. The model implies a near-term upside to the quarterly target of +49.06% and to the monthly target of +28.30%. Forecasts are model-based projections and not guarantees. For more, see the company page on Meyka: /stocks/1518.HK.

Sector context and peer comparison for 1518.HK stock

New Century sits in the Healthcare sector on the HKSE, where average PE is about 26.76. The company’s P/S 0.31 and EV/Sales 0.09 trade well below sector averages, highlighting value versus peers. However, recent financial growth shows revenue down 9.28% year-over-year and net income down 43.71% in the last fiscal year. Sector weakness in medical services and small-cap healthcare volatility weigh on sentiment.

Risks, catalysts and trading considerations for 1518.HK stock

Key risks include continued earnings weakness, low liquidity, and market-wide pressure on Chinese healthcare names. The company reports an upcoming earnings announcement on 26 Mar 2026, which could be a catalyst. Analysts note solid cash coverage metrics and interest coverage 11.26, but return on equity is negative at -8.34%. Short-term traders should size positions carefully and monitor intraday spreads and order book depth.

Final Thoughts

1518.HK stock is a top intraday loser after a -18.46% drop to HK$0.53 on 06 Mar 2026. Valuation metrics look cheap with P/S 0.31 and P/B 0.47, but negative earnings and falling revenue create downside risk. Technically, the stock is oversold with RSI 19.63 and key support at HK$0.52 and the year low HK$0.42. Meyka AI’s forecast model projects a quarterly target of HK$0.79, implying +49.06% upside from today’s price, and a monthly target of HK$0.68 (+28.30%). These model targets suggest recovery potential, but forecasts are model-based projections and not guarantees. Traders should watch the earnings release on 26 Mar 2026 and manage position size given thin liquidity and sector volatility. Meyka AI provides this as data-driven market analysis and these grades are informational only; we are not financial advisors.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.